Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Labcyte BLOG

Labcyte's Road to Commercialization - an Interview with Mark Fischer-Colbrie at PMWC Silicon Valley 2017
THURSDAY, MARCH 09, 2017
linkedin twitter facebook |  28Shares

The recent PMWC Silicon Valley event held in late January at the Computer History Museum in Mountain View, CA, boasted 10,000 attendees and 1,500 speakers. Topics at the event ran the gamut from patent and law policies, economics and emerging technologies to clinical enablement and genomic data analysis. One of our favorite sessions was an onstage discussion between Alex De Winter of GE Ventures and our CEO, Mark Fischer-Colbrie. Titled “How to Commercialize Technologies that Advance PM,” their conversation focused on Labcyte’s path to monetization and commercialization in the realm of precision medicine.


Fischer-Colbrie started with a brief introduction and history of Labcyte, and acoustic dispensing and how it eliminates the problems inherent to pipetting, as well as current adoption and markets. He also mentioned its significant impact, citing drugs both repurposed and brought to market, leukemia patients now in remission and the development of new diagnostics. Next, the conversation focusing on advice for startups to break into new markets and find early adopters, who for Labcyte were “often the people who come up with novel workflows” and who tended to evangelize about the platform during major conferences.


»  WATCH THE VIDEO


Fischer-Colbie asserted that end user benefit was one of the most important factors in highlighting the enormous cost and data quality advances. The accuracy of precision is incredibly powerful, which led to a team at Helsinki’s Institute of Molecular Medicine discovering the precision medicine application for acoustic handling. Fischer-Cobrie’s vision extends beyond precision medicine, and incorporates entire U.S. and global healthcare system. Massive cost savings and tremendous data quality will help get drugs to market faster, enable better diagnostics, and allow researchers to take advantage of big data collections.


With his 30+ years of experience and knowledge of taking three companies public, Fischer-Colbrie was well-positioned to answer De Winter’s many questions. He offered the perfect blend of practical advice and insight for fledgling companies to increase adoption, access new markets and attain commercialization.